Clinical experience with triptans
© Springer-Verlag Italia 2001
Many drugs are now available for treating migraine attacks, including agents specifically indicated for this condition. Since 1990 sumatriptan, the first 5–HT1B,1D receptor agonist, was introduced and realized a real breakthrough in therapy; other agents of this class of drugs called triptans have more recently been used. All of them are effective in relieving the symptoms of migraine, but each exhibits pharmacological and/or clinical features that must be considered for the optimal care and management of the patient. We present here a short overview on the main clinical features of the triptans already in use in Italy.